DERM vs. IFRX, LABP, SCYX, ASMB, MNOV, RLYB, LTRN, VHAQ, ANVS, and LPTX
Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include InflaRx (IFRX), Landos Biopharma (LABP), SCYNEXIS (SCYX), Assembly Biosciences (ASMB), MediciNova (MNOV), Rallybio (RLYB), Lantern Pharma (LTRN), Viveon Health Acquisition (VHAQ), Annovis Bio (ANVS), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
InflaRx (NASDAQ:IFRX) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability, community ranking and media sentiment.
InflaRx received 232 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 64.19% of users gave InflaRx an outperform vote.
InflaRx has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
InflaRx has a net margin of 0.00% compared to InflaRx's net margin of -5.20%. InflaRx's return on equity of -32.83% beat Journey Medical's return on equity.
In the previous week, Journey Medical had 3 more articles in the media than InflaRx. MarketBeat recorded 8 mentions for Journey Medical and 5 mentions for InflaRx. Journey Medical's average media sentiment score of 0.94 beat InflaRx's score of -0.09 indicating that InflaRx is being referred to more favorably in the media.
42.4% of InflaRx shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 19.4% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Journey Medical has higher revenue and earnings than InflaRx. Journey Medical is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.
InflaRx currently has a consensus price target of $13.50, indicating a potential upside of 728.22%. Journey Medical has a consensus price target of $8.50, indicating a potential upside of 146.38%. Given Journey Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe InflaRx is more favorable than Journey Medical.
Summary
InflaRx beats Journey Medical on 10 of the 18 factors compared between the two stocks.
Get Journey Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Journey Medical Competitors List
Related Companies and Tools
